Clinical Trials | March 07, 2026
Roche’s Gazyva shows breakthrough results in Lupus phase III trial
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Subscribe To Our Newsletter & Stay Updated
